By Candice Choi

Don’t even think of putting the mask away anytime soon.

Despite the expected arrival of COVID-19 vaccines in just a few weeks, it could take several months — probably well into 2021 — before things get back to something close to normal in the U.S. and Americans can once again go to the movies, cheer at an NBA game or give Grandma a hug.

The first, limited shipments of the vaccine would mark just the beginning of what could be a long and messy road toward the end of the pandemic that has upended life and killed more than a quarter-million people in the U.S. In the meantime, Americans are being warned not to let their guard down.

“If you’re fighting a battle and the cavalry is on the way, you don’t stop shooting; you keep going until the cavalry gets here, and then you might even want to continue fighting,” Dr. Anthony Fauci, the nation's top infectious-disease expert, said last week.

This week, AstraZeneca became the third vaccine maker to say early data indicates its shots are highly effective. Pfizer last week asked the U.S. Food and Drug Administration for emergency authorization to begin distributing its vaccine, and Moderna is expected to do the same any day. Federal officials say the first doses will ship within a day of authorization.

But most people will probably have to wait months for shots to become widely available. The Pfizer and Moderna vaccines also each require two doses, meaning people will have to go back for a second shot after three and four weeks, respectively, to get the full protection.

Moncef Slaoui, head of the U.S. vaccine development effort, said on CNN on Sunday that early data on the Pfizer and Moderna shots suggest about 70% of the population would need to be vaccinated to achieve herd immunity — a milestone he said is likely to happen in May.

But along the way, experts say the logistical challenges of the biggest vaccination campaign in U.S. history and public fear and misinformation could hinder the effort and kick the end of the pandemic further down the road.

“It’s going to be a slow process and it’s going to be a process with ups and downs, like we’ve seen already,” said Dr. Bill Moss, an infectious-disease expert at Johns Hopkins University.

SHOTS IN ARMS

Once federal officials give a vaccine the go-ahead, doses that are already being stockpiled will be deployed with the goal of “putting needles in people’s arms” within 24 to 48 hours, said Paul Mango, a U.S. Department of Health and Human Services official involved in the Operation Warp Speed effort to develop COVID-19 vaccines.

Those first shipments are expected to be limited and will be directed to high-risk groups at designated locations, such as front-line health care workers at hospitals.

Federal and state officials are still figuring out exactly how to prioritize those most at risk, including the elderly, prison inmates and homeless people. By the end of January, HHS officials say, all senior citizens should be able to get shots, assuming a vaccine becomes available by the end of 2020.

For everyone else, they expect widespread availability of vaccines would start a couple of months later.

To make shots easily accessible, state and federal officials are enlisting a vast network of providers, such as pharmacies and doctor’s offices.

But some worry long lines won’t be the problem.

“One of the things that may be a factor that hasn’t been discussed that much is: ‘How many will be willing to be vaccinated?’” said Christine Finley, director of Vermont's immunization program. She noted the accelerated development of the vaccine and the politics around it have fueled worries about safety.

Even if the first vaccines prove as effective as suggested by early data, they won’t have much impact if enough people don’t take them.

NO MAGIC BULLET

Vaccines aren’t always effective in everyone: Over the past decade, for example, seasonal flu vaccines have been effective in about 20% to 60% of people who get them.

AstraZeneca, Pfizer, and Moderna say early trial data suggests their vaccine candidates are about 90% or more effective. But those rates could change by the time the studies end.

Also, the definition of “effective” can vary.

Rather than prevent infection entirely, the first COVID-19 vaccines might only prevent illness. Vaccinated people might still be able to transmit the virus, another reason experts say masks will remain crucial for some time.

Another important aspect of vaccines: They can take a while to work.

The first shot of a COVID-19 vaccine might bring about a degree of protection within a couple of weeks, meaning people who get infected might not get as sick as they otherwise would. But full protection could take up to two weeks after the second shot -- or about six weeks after the first shot, said Deborah Fuller, a vaccine expert at the University of Washington.

People who don’t understand that lag could mistakenly think the vaccine made them sick if they happen to come down with COVID-19 soon after a shot. People might also blame the vaccine for unrelated health problems and amplify those fears online.

“All you need is a few people getting on social media,” said Moss of Johns Hopkins University.

There's also the possibility of real side effects. COVID-19 vaccine trials have to include at least 30,000 people, but the chances of a rare side effect turning up are more likely as growing numbers of people are vaccinated.

Even if a link between the vaccine and a possible side effect seems likely, the distribution of shots might not be halted if the risk is deemed small and is outweighed by the benefits, said Dr. Wilbur Chen, a vaccine expert at the University of Maryland.

But Chen said public health officials will need to clearly explain the relative risks to avoid public panic.

Depending on whether the virus mutates in coming years and how long the vaccine’s protection lasts, booster shots, later on, may also be necessary, said Dr. Edward Belongia, a vaccine researcher with the Marshfield Clinic Research Institute in Wisconsin.

Belongia and many others say the coronavirus won’t ever be stamped out and will become one of the many seasonal viruses that sicken people. How quickly will vaccines help reduce the threat of the virus to that level?

“At this point, we just need to wait and see,” Belongia said.

——

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Share:
More In Science
New Study Shows Chatbots Help Prevent Eating Disorders
Ellen Fitzsimmons-Craft, assistant professor of psychiatry at Washington University School of Medicine, joins Cheddar News to discuss how chatbots can help prevent eating disorders and the research that uncovered these findings.
Why The Human Shoulder Is A Design Disaster
Shoulder injuries are one of the most common orthopedic injuries – and they're also one of the most commonly ignored. But chimpanzees, with whom we share nearly 99% of our DNA, don’t encounter the same issues we do. So why are human shoulders such a design disaster? Well, we can trace the answer back to a very particular moment in our evolution.
Nurses Call For Protection For HealthCare Workers
As the Omicron variant continues to sweep across the country. The US Supreme Court is expected to hear arguments at the end of this week on whether or not the Biden administration can force private companies to vaccinate or test millions of their employees. In addition, the National Nurses United has spearheaded legal action to protect nurses and health care workers, patients, and the public while on the job. President of the National Nurses Union, Zenei Cortez, joined Cheddar to discuss more.
Pear Therapeutics CEO on How Its Apps Work for Conditions Like Addiction
Digital medical care provider Pear Therapeutics rang the closing bell on the Nasdaq Friday and President and CEO Dr. Corey McCann, joined Cheddar to talk about how the company plans to grow the business of software-based therapeutics and how the first FDA authorized prescription digital therapeutics company will go about treating illnesses like insomnia and addiction. "These really are pieces of software. In many cases, they're apps and in the cases of our addiction products, these are based on something called cognitive behavioral therapy or CBT," he said. "These products change the patient's brain circuitry to help them be abstinent, to help them stay in treatment, and that's exactly what we see in randomized clinical trials and that's what we see in the real world." He also addressed the ongoing mental health crises brought on by the pandemic. **copy updated to remove IPO information as Pear Therapeutics went public in December**
Virgin Orbit Goes Public One Week Before 'Above the Clouds' Space Mission
Satellite launch service Virgin Orbit has gone public on the Nasdaq via a SPAC merger with NextGen Acquisitions with a valuation of about $3.2 billion. CEO Dan Hart joined Cheddar's "Between Bells" from in front of his LauncherOne rocket in New York City's Times Square to talk about what's next after the IPO, an upcoming "Above the Clouds" mission to deliver commercial and national security payloads, and the benefits of their rockets being launched from commercial 747 aircraft. "We can launch anywhere in the world," he said. "There are almost 80 space agencies across the world, for instance, and about 10 of them have space launch. We can give them a space flight capability overnight by taking a runway and turning it into a spaceport."
Cheddar Climate: The Fight for Change 2021 Year-End Special
The year 2021 saw numerous natural disasters around the world, including extreme heat and wildfires, rare deep freezes, and historic flooding. This year's United Nations COP26 conference was key for getting world leaders on board with emissions reductions and other climate-focused policies as the UN Secretary-General said the agency's report on global warming is a 'code red for humanity.' In the U.S., President Joe Biden has focused most of his domestic agenda on slashing emissions and building climate-focused infrastructure. Guests from The Economist, UNC-Chapel Hill, Global Rescue, and more join Cheddar Climate's year-end special to discuss how the climate changed in 2021, and what to expect in 2022.
Little Otter Raises $22 Million Series A to Combat the Children's Mental Health Crisis
Digital mental health company Little Otter recently announced it closed a $22 million Series A round. Little Otter was founded in 2020 by a mother-daughter team, which based the company on the idea that a child's mental health can only be addressed by treating the whole family through technology available to everyone. Little Otter CEO and co-founder Rebecca Egger and her mother, Little Otter Chief Medical and Scientific Officer and co-founder Dr. Helen Egger joined Cheddar News' Closing Bell to discuss.
The Truth About "Rising" Male Infertility
Among all the other events of the last few years, you may have missed this one: Spermageddon. This is the fun name for the idea that sperm counts among mainly ‘Western’ men are in freefall. The Spermageddon hype began with the publication of a 2017 study showing a nearly 60% drop in overall sperm counts in men living in North America, Europe, Australia, and New Zealand. But four years later, it seems that Spermageddon has been overblown. By a lot. And all that hype has obscured the real issue behind declining male fertility.
How Covid-19 Has Changed Our Mental Health World; Wellness Trends to Watch in 2022
Covid-19 has changed the way we view wellness. Jillian Hughes, communications director of Mental Health America, joins Cheddar News to discuss breaking the stigma around mental health. Justin Davis, CEO and co-founder of Spectrum Labs, weighs in on how social media impacts our wellbeing. Lastly, Precision Nutrition CEO Timothy Jones advices us on what trends to watch in 2022.
Load More